These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9266736)

  • 1. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
    Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
    Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
    Quattrone A; Zappia M; Aguglia U; Branca D; Colao R; Montesanti R; Nicoletti G; Palmieri A; Parlato G; Rizzo M
    Ann Neurol; 1995 Sep; 38(3):389-95. PubMed ID: 7668824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short- and long-duration responses to levodopa during the first year of levodopa therapy.
    Nutt JG; Carter JH; Van Houten L; Woodward WR
    Ann Neurol; 1997 Sep; 42(3):349-55. PubMed ID: 9307256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the response to levodopa during the first 4 years of therapy.
    Nutt JG; Carter JH; Lea ES; Sexton GJ
    Ann Neurol; 2002 Jun; 51(6):686-93. PubMed ID: 12112073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
    Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
    Nutt JG; Holford NH
    Ann Neurol; 1996 May; 39(5):561-73. PubMed ID: 8619540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.
    Anderson E; Nutt J
    Parkinsonism Relat Disord; 2011 Sep; 17(8):587-92. PubMed ID: 21530356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Brissenden JA; Scerbak T; Albin RL; Lee TG
    Mov Disord; 2024 Jan; 39(1):76-84. PubMed ID: 38062630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
    Djaldetti R; Melamed E
    Ann Neurol; 1996 Mar; 39(3):400-4. PubMed ID: 8602763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.